{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rapamycin&page=26", "query": { "intervention": "rapamycin", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 647, "total_pages": 65, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rapamycin&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rapamycin&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T03:46:19.584Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00708591", "title": "Study of Rapamycin Plus Ketoconazole in Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Rapamycin", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2004-10", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00708591" }, { "nct_id": "NCT01337765", "title": "Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific", "Solid Tumor" ], "interventions": [ { "name": "BEZ235 + MEK162", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2011-07-08", "completion_date": "2013-03-22", "has_results": false, "last_update_posted_date": "2020-10-09", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01337765" }, { "nct_id": "NCT00920309", "title": "Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Autosomal Dominant Polycystic Kidney Disease" ], "interventions": [ { "name": "Rapamycin", "type": "DRUG" }, { "name": "Standard of Care-Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2009-06", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2014-04-14", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00920309" }, { "nct_id": "NCT03952637", "title": "A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lysosomal Diseases", "Gangliosidosis", "GM1" ], "interventions": [ { "name": "AAV9-GLB1", "type": "BIOLOGICAL" }, { "name": "Abdominal ultrasound", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Audiology assessment with ABR", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone density scan (DEXA)", "type": "DIAGNOSTIC_TEST" }, { "name": "Electrocardiogram (EKG)", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "Electroencephalogram (EEG) awake and extended overnight", "type": "OTHER" }, { "name": "Laboratory tests", "type": "DIAGNOSTIC_TEST" }, { "name": "Lumbar puncture", "type": "PROCEDURE" }, { "name": "Brain MRI/MRS/fMRI", "type": "PROCEDURE" }, { "name": "Neurocognitive testing", "type": "BEHAVIORAL" }, { "name": "Neurology exam", "type": "OTHER" }, { "name": "PICC or other Central line placement", "type": "BEHAVIORAL" }, { "name": "Skeletal survey", "type": "PROCEDURE" }, { "name": "Skin biopsy", "type": "PROCEDURE" }, { "name": "Speech and modified barium swallow study", "type": "PROCEDURE" }, { "name": "Ophthalmology exam", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "DIAGNOSTIC_TEST", "OTHER", "BEHAVIORAL" ], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Months to 12 Years" }, "enrollment_count": 54, "start_date": "2019-08-19", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03952637" }, { "nct_id": "NCT00975819", "title": "Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kaposiform Hemangioendotheliomas", "Tufted Angioma", "Capillary Venous Lymphatic Malformation", "Venous Lymphatic Malformation", "Microcystic Lymphatic Malformation", "Mucocutaneous Lymphangiomatosis and Thrombocytopenia", "Capillary Lymphatic Arterial Venous Malformations", "PTEN Overgrowth Syndrome With Vascular Anomaly", "Lymphangiectasia Syndromes" ], "interventions": [ { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Denise Martin Adams", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "31 Years", "sex": "ALL", "summary": "Up to 31 Years" }, "enrollment_count": 61, "start_date": "2009-10", "completion_date": "2020-10", "has_results": true, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Cincinnati, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975819" }, { "nct_id": "NCT02619669", "title": "Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TAK-228", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gary Schwartz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2017-04-20", "completion_date": "2019-06-14", "has_results": false, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02619669" }, { "nct_id": "NCT00703170", "title": "Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Resistant Solid Malignancies" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2008-03", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2013-05-24", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00703170" }, { "nct_id": "NCT00770263", "title": "Erlotinib and Temsirolimus for Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2009-05", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00770263" }, { "nct_id": "NCT05103358", "title": "Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumor", "Tumor, Solid", "Metastasis", "Metastatic Cancer", "Cancer", "Cancer Metastatic", "Tumors", "Neoplasms", "Neoplasm Metastasis", "Solid Tumor", "Advanced Solid Tumor", "Advanced Cancer", "Malignant Solid Tumor", "Malignant Solid Neoplasm", "Malignant Neoplasm", "Malignant Tumor", "TSC", "TSC1", "TSC2", "Metastatic Solid Tumor", "Metastatic Neoplasm" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 128, "start_date": "2022-03-10", "completion_date": "2024-12-23", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 159, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05103358" }, { "nct_id": "NCT07144150", "title": "EVERO Drug-coated Balloon (DCB) Randomized Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Peripheral Vascular Disease", "Peripheral Arterial Disease" ], "interventions": [ { "name": "Evero DCB", "type": "COMBINATION_PRODUCT" }, { "name": "Paclitaxel DCB", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Cook Research Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2026-04-17", "completion_date": "2032-10", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-20T03:46:19.584Z", "location_count": 12, "location_summary": "Long Beach, California • New Haven, Connecticut • Gainesville, Florida + 9 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07144150" } ] }